Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial
Article in BMC Ophthalmology (July 2024)
The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.
Evaluation of dry eye disease symptomatology and mental health status among patients with different COVID-19 statuses
Article in International Journal of Ophthalmology (May 2024)
Prevalence and Risk Factors of Dry Eye Syndrome in University Students
Article in The Korean Journal of Vision Science (December 2023)